R. Becker

J. Kasprzak, R. Becker, R. Mehran, 2014, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Factor IXa as a target for anticoagulation in thrombotic disorders and conditions.

R. Becker, Dia A Smiley, Dia A. Smiley, 2014, Drug discovery today.

Safety of very early sheath removal in patients treated with REG1 for acute coronary syndromes: insights from the RADAR trial.

J. Kasprzak, R. Becker, R. Mehran, 2013, The Journal of invasive cardiology.

Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY.

Sunil V. Rao, R. Califf, E. Antman, 2010, International Journal of Cardiology.

Bridging the gap between clinical trials of antiplatelet therapies and applications among elderly patients.

Deepak L. Bhatt, H. Dauerman, R. Becker, 2010, American heart journal.

Evaluation of a New Heparin Agent in Percutaneous Coronary Intervention: Results of the Phase 2 Evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial

Sunil V. Rao, R. Becker, J. Alexander, 2010, Circulation.

Design and rationale of the Evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) trial.

Sunil V. Rao, R. Becker, A. Kosinski, 2009, American Heart Journal.

Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes

C. Held, C. Cannon, A. Budaj, 2017, American heart journal.

New Thrombolytics, Anticoagulants, and Platelet Antagonists: The Future of Clinical Practice

R. Becker, 1999, Journal of Thrombosis and Thrombolysis.

Surface 12-lead electrocardiographic findings and plasma markers of thrombin activity and generation in patients with myocardial ischemia at rest

K. Mann, R. Becker, S. Baker, 1994, Journal of Thrombosis and Thrombolysis.

Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I Trial. GUSTO-I Hemostasis Substudy Group. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries.

R. Califf, E. Topol, C. Granger, 1998, Journal of the American College of Cardiology.

Platelet activation and its patient-specific consequences.

S. Steinhubl, R. Becker, S. Smyth, 2008, Thrombosis research.

Cardiac rupture associated with thrombolytic therapy: impact of time to treatment in the Late Assessment of Thrombolytic Efficacy (LATE) study.

A. Skene, E. Topol, J. Gore, 1995, Journal of the American College of Cardiology.

Association of the coronary artery disease risk gene GUCY1A3 with ischaemic events after coronary intervention.

J. Erdmann, H. Schunkert, N. Eriksson, 2019, Cardiovascular research.

Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry.

K. Anstrom, S. Steinhubl, E. Ohman, 2009, American Heart Journal.

Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.

C. Held, C. Cannon, K. Mahaffey, 2011, Circulation.

Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.

C. Held, C. Cannon, K. Mahaffey, 2011, Journal of the American College of Cardiology.

Identification, Diagnosis and Treatment of Heparin-induced Thrombocytopenia and Thrombosis: A Registry of Prolonged Heparin Use and Thrombocytopenia among Hospitalized Patients with and without Cardiovascular Disease

K. Anstrom, E. Ohman, C. Granger, 2005, Journal of Thrombosis and Thrombolysis.

Cardiac tamponade in the fibrinolytic era: analysis of >100,000 patients with ST-segment elevation myocardial infarction.

R. Califf, F. Van de Werf, H. White, 2006, American heart journal.

Bleeding-associated outcomes with preoperative clopidogrel use in on- and off-pump coronary artery bypass

S. Steinhubl, R. Becker, J. Berger, 2012, Journal of Thrombosis and Thrombolysis.

The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome

L. Wallentin, R. Becker, S. James, 2011, Thrombosis and Haemostasis.

Coronary Artery Bypass Surgery: A Multicenter Analysis Impact of Clopidogrel in Patients With Acute Coronary Syndromes Requiring

R. Becker, J. Berger, F. Edwards, 2008 .

Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis.

S. Steinhubl, R. Becker, J. Berger, 2008, Journal of the American College of Cardiology.

Acute Coronary Syndromes Impact of Clopidogrel in Patients With Acute Coronary Syndromes Requiring Coronary Artery Bypass Surgery

S. Steinhubl, R. Becker, J. Berger, 2008 .

Focus on thrombosis

R. Becker, 2007, Journal of Thrombosis and Thrombolysis.

Acute myocardial infarction: Antithrombotic therapy

R. Becker, 2003, Current treatment options in cardiovascular medicine.

Complicated myocardial infarction.

R. Becker, 2003, Critical pathways in cardiology.

Unraveling the Genetic Basis of Recurrent Venous Thromboembolism

D. Voora, R. Becker, 2018 .

Proinflammatory, immunomodulating, and prothrombotic properties of anemia and red blood cell transfusions

Sunil V. Rao, R. Becker, Katie M. Twomley, 2006, Journal of Thrombosis and Thrombolysis.

Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding.

Deepak L. Bhatt, Sunil V. Rao, M. Price, 2013, Journal of the American College of Cardiology.

The safety of warfarin therapy in the nursing home setting.

Nancy Verzier, Terry S Field, Jerry H Gurwitz, 2007, The American journal of medicine.

Comparison of long-term outcomes between older Asian and white patients with non-ST-segment elevation myocardial infarction: findings from CRUSADE-CMS database.

E. Peterson, R. Becker, M. Roe, 2013, American heart journal.

Medical Therapy for Acute Myocardial Infarction: Where Do We Go from Here?

R. Becker, 1995 .

Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial.

C. Held, C. Cannon, K. Mahaffey, 2014, Journal of the American College of Cardiology.

Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST-segment elevation acute coronary syndromes treated with unfractionated heparin

Michael P. Thomas, R. Califf, E. Antman, 2012, Journal of Thrombosis and Thrombolysis.

Platelet P2Y12 receptor antagonist pharmacokinetics and pharmaco -dynamics: A foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies

R. Becker, P. Gurbel, 2010, Thrombosis and Haemostasis.

Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.

A. Skene, C. Cannon, L. Wallentin, 2009, American heart journal.

Noninvasive, medical management for non-ST-elevation acute coronary syndromes.

P. Armstrong, H. White, E. Ohman, 2008, American heart journal.

Cardiac Rupture After Myocardial Infarction: New Insights From Murine Models

R. Becker, D. Sane, W. Mozingo, 2009, Cardiology in review.

Exploring the medical need for alternate site testing. A clinician's perspective.

R. Becker, 1995, Archives of pathology & laboratory medicine.

Early withdrawal of statin therapy in patients with non-ST-segment elevation myocardial infarction: national registry of myocardial infarction.

J. Gore, R. Goldberg, G. Fonarow, 2004, Archives of internal medicine.

Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium

R. Becker, J. Berger, G. Vilahur, 2022, Nature Reviews Cardiology.

Anticoagulation and Monitoring of a Novel and Reversible Factor IXa Inhibitor

R. Becker, T. Povsic, M. Chan, 2013 .

Nucleic acid aptamers as antithrombotic agents: Opportunities in extracellular therapeutics

B. Sullenger, R. Becker, T. Povsic, 2010, Thrombosis and Haemostasis.

Protein-Binding Oligonucleotides: The Next Frontier in Antithrombotic Therapy

R. Becker, 2004, Journal of Thrombosis and Thrombolysis.

Association of Blood Pressure Level With Left Ventricular Mass in Adolescents.

Lisa J. Martin, B. Rosner, S. Daniels, 2019, Hypertension.

Serum gamma-glutamyl transpeptidase and chronic alcoholism. Influence of alcohol ingestion and liver disease.

R. Becker, E. Mezey, R. Bozian, 1985, Digestive diseases and sciences.

Early and Pre-Discharge Aspirin Administration Among Patients with Acute Myocardial Infarction: Current Clinical Practice and Trends in the United States

J. Gore, W. Rogers, R. Becker, 2000, Journal of Thrombosis and Thrombolysis.

Understanding the dynamics of thrombin in cardiovascular disease: pathobiology and biochemistry for the clinician.

R. Becker, 2005, American heart journal.

The decision to perform coronary bypass surgery in women. What are the facts?

J. Alpert, R. Becker, J. Corrao, 1988, American heart journal.

Inhibition and Patient Outcomes (PLATO) Trial In-Hospital Revascularization: A Substudy From the Prospective Randomized Platelet ST-Elevation Acute Coronary Syndrome Patients Managed With or Without − Non Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in

C. Held, C. Cannon, K. Mahaffey, 2014 .

Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non–ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization: A Substudy From the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) Trial

C. Held, C. Cannon, K. Mahaffey, 2014, Circulation.

Choice of agents to limit the coagulation cascade in acute coronary syndromes

R. Becker, 2002, Current cardiology reports.

A critical review of clinical trials for low‐molecular‐weight heparin therapy in unstable coronary artery disease

R. Becker, S. Husted, A. Kher, 2001, Clinical cardiology.

Heparins in management of acute coronary syndromes without ST-segment elevation

R. Becker, 2000, The Lancet.

Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy.

K. Anstrom, S. Steinhubl, E. Ohman, 2008, Archives of internal medicine.

Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes.

E. Antman, S. Murphy, R. Becker, 2002, American heart journal.

Six-month follow-up of patients with in-hospital thrombocytopenia during heparin-based anticoagulation (from the Complications After Thrombocytopenia Caused by Heparin [CATCH] registry).

K. Anstrom, E. Ohman, C. Granger, 2009, The American journal of cardiology.

Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial.

R. Califf, E. Antman, H. White, 2010, International journal of cardiology.

Contribution of bleeding and thromboembolic events to in-hospital mortality among patients with thrombocytopenia treated with heparin.

K. Anstrom, E. Ohman, C. Granger, 2009, The American journal of cardiology.

Antithrombotic therapy in heparin-induced thrombocytopenia: guidelines translated for the clinician

R. Becker, R. Lopes, J. Alexander, 2012, Journal of Thrombosis and Thrombolysis.

Effects of Prior Aspirin and Anti-Ischemic Therapy on Outcome of Patients With Unstable Angina 1

E. Antman, E. Braunwald, C. Cannon, 1998 .

Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina. TIMI 7 Investigators. Thrombin Inhibition in Myocardial Ischemia.

E. Antman, E. Braunwald, C. Cannon, 1998, The American journal of cardiology.

Pulmonary embolism: a review of 200 cases with emphasis on pathophysiology, diagnosis, and treatment.

R. Becker, R. Graor, J. Holloway, 1984, Cleveland Clinic quarterly.

Impact of home warfarin use on treatment patterns and bleeding complications for patients with non-ST-segment elevation acute coronary syndromes: observations from the CRUSADE quality improvement initiative.

W. Gibler, E. Ohman, E. Peterson, 2008, European heart journal.

Association of intronic DNA methylation and hydroxymethylation alterations in the epigenetic etiology of dilated cardiomyopathy.

R. Becker, R. Knöll, S. Sadayappan, 2019, American journal of physiology. Heart and circulatory physiology.

Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q-wave myocardial infarction (TIMI IIIB Trial)

C. Cannon, E. Braunwald, G. Knatterud, 1996, The American journal of cardiology.

Mental stress-induced left ventricular dysfunction and adverse outcome in ischemic heart disease patients

C. O'connor, R. Becker, C. Kuhn, 2017, European journal of preventive cardiology.

Thrombin: Structure, Biochemistry, Measurement, and Status in Clinical Medicine

R. Becker, F. Spencer, 1998, Journal of Thrombosis and Thrombolysis.

PAR-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with atherothrombosis.

R. Becker, S. Leonardi, 2012, Handbook of experimental pharmacology.

Thrombin Receptor Antagonists for the Treatment of Atherothrombosis

R. Becker, P. Tricoci, S. Leonardi, 2010, Drugs.

Protease-activated receptor-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with acute coronary syndrome.

R. Becker, P. Tricoci, S. Leonardi, 2012, Advances in cardiology.

Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome.

C. Cannon, W. Weaver, A. Siegbahn, 2017, Clinical chemistry.

College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy: Future Directions

K. Mann, R. Becker, D. Phillips, 1998 .

Improving the efficacy and stability of coronary reperfusion following thrombolysis: Exploring the thrombin hypothesis

R. Becker, 2005, Journal of Thrombosis and Thrombolysis.

Determining the efficacy of antiplatelet therapies for the individual: lessons from clinical trials

S. Steinhubl, R. Becker, D. Schneider, 2008, Journal of Thrombosis and Thrombolysis.

Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events.

W. Kraus, G. Ginsburg, J. Lucas, 2013, Journal of the American College of Cardiology.

COVID-19 update: Covid-19-associated coagulopathy

R. Becker, 2020, Journal of Thrombosis and Thrombolysis.

Comparative Effects of Unfractionated Heparin and Low Molecular Weight Heparin on Vascular Endothelial Cell Tissue Factor Pathway Inhibitor Release: A Model for Assessing Intrinsic Thromboresistance

R. Becker, F. Spencer, Youfu Li, 2002, Journal of Thrombosis and Thrombolysis.

Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa receptor-directed platelet inhibition.

R. Becker, F. Spencer, Youfu Li, 2001, American heart journal.

Platelets in atherothrombosis.

R. Becker, D. Vorchheimer, 2006, Mayo Clinic proceedings.

First experience with direct, selective factor Xa inhibition in patients with non‐ST‐elevation acute coronary syndromes: results of the XaNADU‐ACS Trial

P. Armstrong, R. Becker, J. Alexander, 2005, Journal of thrombosis and haemostasis : JTH.

Recent update to the ACC/AHA guidelines for the management of patients with unstable angina and non‐st‐segment elevation myocardial infarction: Role of antiplatelet therapy

R. Becker, 2004, Clinical cardiology.

Monitoring thrombolytic therapy.

R. Becker, R. Tracy, E. Bovill, 1992, Progress in cardiovascular diseases.

Tools for noninvasive assessment of coronary arterial reperfusion.

R. Becker, 1992, Cleveland Clinic journal of medicine.

Point-of-care platelet function tests: relevance to arterial thrombosis and opportunities for improvement

R. Becker, Diana A Gorog, 2020, Journal of Thrombosis and Thrombolysis.

The unmet need for philanthropic funding of early career cardiovascular investigators

R. Becker, T. Ahmad, 2014, Journal of Thrombosis and Thrombolysis.

Antithrombotic therapy after myocardial infarction.

R. Becker, 2002, The New England journal of medicine.

ABO blood group influences transfusion and survival after cardiac surgery

Sunil V. Rao, R. Becker, M. Newman, 2014, Journal of Thrombosis and Thrombolysis.

Association between serial measures of systemic blood pressure and early coronary arterial perfusion status following intravenous thrombolytic therapy

R. Becker, R. Luippold, S. Ball, 1994, Journal of Thrombosis and Thrombolysis.

Achieving optimal reperfusion without adjunctive antithrombotic therapy: Novel thrombolytic dosing strategies

R. Becker, 2005, Journal of Thrombosis and Thrombolysis.

Importance of clinical trials in developing safe and effective treatments for acute myocardial infarction: From TIMI II to TIMI 9, GUSTO II, and HIT III

R. Becker, 1995, Journal of Thrombosis and Thrombolysis.

Thrombin Generation, Inhibition and Clinical Outcomes in Patients With Acute Myocardial Infarction Treated With Thrombolytic Therapy and Heparin: Results From the GUSTO-I Trial fn1fn1This study was supported by Genentech, Inc., South San Francisco, California; Bayer Corporation, New York, New York;

R. Califf, E. Topol, C. Granger, 1998 .

Update : Systemic Diseases and the Cardiovascular System ( VI ) Hematologic Diseases : From Within the Heart

R. Becker, Weixian Xu, Tracy Y. Wang, 2017 .

Puesta al dı́a : Enfermedades sistémicas y corazón ( VI ) Enfermedades hematológicas : desde dentro del corazón

R. Becker, Weixian Xu, Tracy Y. Wang, 2011 .

Enfermedades hematologicas: desde dentro del corazon

R. Becker, Weixian Xu, Tracy Y. Wang, 2011 .

[Hematologic diseases: from within the heart].

R. Becker, Weixian Xu, Tracy Y. Wang, 2011, Revista espanola de cardiologia.

Aspirin and the prevention of venous thromboembolism.

R. Becker, 2012, The New England journal of medicine.

Thrombosis and the role of the platelet.

R. Becker, 1999, The American journal of cardiology.

Pharmacogenetics and safety parameters for platelet P2Y12 receptor antagonists

R. Becker, 2009, Journal of Thrombosis and Thrombolysis.

Manesh R. Patel, G. Breithardt, D. Singer, 2014, Stroke.

Beta‐adrenergic blockade following thrombolytic therapy: Is it helpful or harmful?

R. Becker, 1994, Clinical cardiology.

The investigation of biomarkers in cardiovascular disease: time for a coordinated, international effort.

R. Becker, 2005, European heart journal.

The Need for Long-Term Anticoagulants in Venous Thromboembolism: How Long?

R. Becker, J. Ansell, 1997 .

Evaluation of the Patient with Hypotension and Shock

R. Becker, 2001 .

Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.

C. Cannon, L. Wallentin, R. Becker, 2016, American heart journal.

Intravenous nitroglycerin-induced heparin resistance: a qualitative antithrombin III abnormality.

J. Gore, R. Becker, S. Baker, 1990, American heart journal.

A clinician's perspective of emerging P2Y12-directed pharmacotherapies, ex vivo measurement tools, and clinical outcomes

R. Becker, J. Berger, 2009, Platelets.

Age and the utilization of cardiac catheterization following uncomplicated first acute myocardial infarction treated with thrombolytic therapy (The Second National Registry of Myocardial Infarction [NRMI-2]).

J. Gore, R. Goldberg, R. Becker, 2001, The American journal of cardiology.

Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes: potential mechanisms for heightened prothrombotic potential.

R. Becker, F. Spencer, T. Hurley, 1999, Journal of the American College of Cardiology.

Antiplatelet therapy in coronary heart disease. Emerging strategies for the treatment and prevention of acute myocardial infarction.

R. Becker, 1993, Archives of pathology & laboratory medicine.

Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial

Manesh R. Patel, G. Breithardt, D. Singer, 2015, Journal of the American Heart Association.

Management strategies in unstable coronary artery disease—Current problems and future directions

J. Cleland, D. Waters, A. Maseri, 1999, Clinical cardiology.

Effect of elevated leukocyte count on in-hospital mortality following acute myocardial infarction.

R. Goldberg, R. Becker, M. Furman, 1996, The American journal of cardiology.

The scientific community's quest to identify optimal targets for anticoagulant pharmacotherapy.

K. Mahaffey, R. Becker, 2006, Circulation.

Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease.

V. Hasselblad, R. Becker, J. Alexander, 2006, Thrombosis research.

Vascular Endothelial Tissue Factor Pathway Inhibitor Kinetics in Culture Following Exposure to DX-9065a—A Selective and Direct Factor Xa Inhibitor

R. Becker, J. Alexander, R. Harrington, 2004, Journal of Thrombosis and Thrombolysis.

Initial experience with factor‐Xa inhibition in percutaneous coronary intervention: the XaNADU‐PCI Pilot

V. Hasselblad, R. Becker, J. Alexander, 2004, Journal of thrombosis and haemostasis : JTH.

Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease

R. Becker, J. Alexander, R. Harrington, 2004, Thrombosis and Haemostasis.

Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - A direct and selective antagonist

R. Becker, J. Alexander, R. Harrington, 2004, Thrombosis and Haemostasis.

Patient-Specific Antithrombotic Strategies: Lessons Not Yet Learned from the Renal Insufficiency Paradigm

R. Becker, 2005, Journal of Thrombosis and Thrombolysis.

Diagnosis and Management of Inherited and Acquired Thrombophilias

R. Becker, F. Spencer, 1999, Journal of Thrombosis and Thrombolysis.

Interleukin‐18 in patients with acute coronary syndromes

C. Cannon, W. Weaver, A. Siegbahn, 2019, Clinical cardiology.

Anticoagulation in congestive cardiomyopathy: Steps toward defining the great unknown

R. Becker, F. Spencer, 2004, Journal of Thrombosis and Thrombolysis.

Autonomic dysfunction in SARS-COV-2 infection acute and long-term implications COVID-19 editor’s page series

R. Becker, 2021, Journal of Thrombosis and Thrombolysis.

Inflammatory Response and Thrombosis in Older Individuals

R. Becker, J. Schlaudecker, 2014, Seminars in Thrombosis & Hemostasis.

The effect of the REG2 Anticoagulation System on thrombin generation kinetics: a pharmacodynamic and pharmacokinetic first-in-human study

R. Becker, T. Povsic, S. Zelenkofske, 2014, Journal of Thrombosis and Thrombolysis.

Bacterial tissue tropism: an in vitro model for infective endocarditis.

R. Becker, P. Dibello, F. Lucas, 1987, Cardiovascular research.

Myocardial infarction in patients undergoing noncardiac surgery.

R. C. Becker, R. Becker, D. Underwood, 1987, Cleveland Clinic journal of medicine.

The Effect of Temperature Variation In Vitro on Platelet-Leukocyte Interactions and Individual Prothrombotic Potential

R. Becker, F. Spencer, Youfu Li, 2004, Journal of Thrombosis and Thrombolysis.

Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes

K. Mahaffey, R. Becker, M. Valgimigli, 2014, Thrombosis and Haemostasis.

Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study

C. Held, C. Cannon, A. Siegbahn, 2013, Platelets.

Response to letter regarding article, "Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials".

C. Cannon, L. Wallentin, R. Becker, 2013, Stroke.

Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.

W. Weaver, C. Grines, R. Becker, 2006, American heart journal.

Thrombolytic retreatment with tissue plasminogen activator for threatened reinfarction and thrombotic coronary reocclusion

R. Becker, 1994, Clinical cardiology.

Hyperreactive platelet phenotypes: Relationship to altered serotonin transporter number, transport kinetics and intrinsic response to adrenergic co-stimulation

F. Dentali, R. Becker, T. Ortel, 2012, Thrombosis and Haemostasis.

Platelets: Developmental biology, physiology, and translatable platforms for preclinical investigation and drug development

Sunil V. Rao, S. Steinhubl, J. Freedman, 2008, Platelets.

Clinical experience with routine activated coagulation time monitoring during elective PTCA

R. Becker, B. Weiner, L. I. Heller, 2005, Journal of Thrombosis and Thrombolysis.

Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardiaL infarction. Thrombolysis in Myocardial Ischemia III B Investigators.

E. Braunwald, C. Cannon, R. Becker, 1996, American heart journal.

Thrombin antagonists and antiplatelet agents.

R. Becker, 1992, The American journal of cardiology.

Editorial: Toward establishing comprehensive universal guidelines for antithrombotic therapy

R. Becker, 1995, Journal of Thrombosis and Thrombolysis.

Cardiology and the critical care crisis: a perspective.

R. Becker, J. Katz, A. Turer, 2007, Journal of the American College of Cardiology.

Markers of platelet activation and thrombin generation

R. Becker, 2007, Cardiovascular Toxicology.

The Prothrombinase Complex: Assembly and Function

R. Becker, F. Spencer, 2004, Journal of Thrombosis and Thrombolysis.

Biochemistry of Intra Vascular Clotting: Focus on the Prothrombinase Complex

R. Becker, F. Spencer, 1997 .

The cleaved peptide of the thrombin receptor is a strong platelet agonist.

R. Becker, M. Furman, Long-bin Liu, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Biomarkers in Atrial Fibrillation: Investigating Biologic Plausibility, Cause, and Effect

R. Becker, 2005, Journal of Thrombosis and Thrombolysis.

Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials

Deepak L. Bhatt, M. Price, R. Becker, 2012, Journal of Thrombosis and Thrombolysis.

Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.

C. Cannon, L. Wallentin, R. Becker, 2010, Journal of the American College of Cardiology.

Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes.

C. Cannon, Richard Cairns, L. Wallentin, 2011, European heart journal.

Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial.

C. Held, C. Cannon, L. Wallentin, 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Factor Xa inhibitors: critical considerations for clinical development and testing

R. Becker, 2021, Journal of Thrombosis and Thrombolysis.

Pentraxin-3 vs C-reactive protein and other prognostic biomarkers in acute coronary syndrome: A substudy of the Platelet Inhibition and Patients Outcomes (PLATO) trial

A. Siegbahn, L. Wallentin, R. Becker, 2020, European heart journal. Acute cardiovascular care.

Emerging Pharmacological Therapy in Patients with Advanced Occlusive Peripheral Vascular Disease

R. Becker, 1995 .

Hemorrhagic potential of combined diltiazem and recombinant tissue-type plasminogen activator administration.

J. Gore, R. Becker, S. Baker, 1993, American heart journal.

Circadian variation in thrombolytic response to recombinant tissue-type plasminogen activator in acute myocardial infarction

J. Alpert, J. Gore, R. Becker, 1988 .

Mechanisms and management of cardiogenic shock.

J. Alpert, R. Becker, Joseph S. Alpert, 1993, Critical care clinics.

Cardiogenic shock: elements of etiology, diagnosis, and therapy.

J. Alpert, R. Becker, Joseph S. Alpert, 1993, Clinical cardiology.

Platelet activation determined by flow cytometry persists despite antithrombotic therapy in patients with unstable angina and non-Q-wave myocardial infarction

K. Mann, R. Becker, R. Tracy, 1994, Journal of Thrombosis and Thrombolysis.

The clinical use of flow cytometry for assessing platelet activation in acute coronary syndromes

K. Mann, R. Becker, R. Tracy, 1994, Coronary artery disease.

Designing Human In Vitro Models for Drug Development.

R. Becker, S. Sadayappan, 2020, Journal of the American College of Cardiology.

C. Cannon, A. Siegbahn, L. Wallentin, 2017, Journal of Thrombosis and Thrombolysis.

Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy).

C. Cannon, L. Wallentin, R. Becker, 2011, The American journal of cardiology.

Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis

C. Held, P. Armstrong, C. Cannon, 2018, American heart journal.

Emerging constructs to maintain safety among patients with acute coronary syndromes requiring surgical coronary revascularization

R. Becker, 2008 .

Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non–ST‐segment elevation acute coronary syndrome in the PLATO trial

C. Cannon, L. Wallentin, R. Becker, 2017, Clinical cardiology.

Advances in Heart Failure Thromboembolism and Antithrombotic Therapy in Patients With Heart Failure in Sinus Rhythm Current Status and Future Directions

C. O'connor, G. Felker, M. Metra, 2011 .

Response to Letter Regarding Article, “Mechanisms of Bleeding and Approach to Patients With Axial-Flow Left Ventricular Assist Devices”

G. Felker, Adrian F. Hernandez, R. Becker, 2012 .

The effect of aspirin on endothelial progenitor cell biology: preliminary investigation of novel properties.

Jason D. Allen, R. Becker, T. Povsic, 2010, Thrombosis research.

CORONARY INTERVENT IONS

C. Held, C. Cannon, L. Wallentin, 2015 .

Anticipating the long-term cardiovascular effects of COVID-19

R. Becker, 2020, Journal of Thrombosis and Thrombolysis.

Association of Blood Pressure–Related Increase in Vascular Stiffness on Other Measures of Target Organ Damage in Youth

S. Daniels, B. Falkner, R. Becker, 2022, Hypertension.

C-X-C Ligand 16 Is an Independent Predictor of Cardiovascular Death and Morbidity in Acute Coronary Syndromes.

A. Siegbahn, L. Wallentin, R. Becker, 2019, Arteriosclerosis, thrombosis, and vascular biology.

Brain‐derived neurotrophic factor rs6265 (Val66Met) polymorphism is associated with disease severity and incidence of cardiovascular events in a patient cohort

Svati H Shah, E. Hauser, R. Becker, 2017, American heart journal.

Calcium channel antagonists in the modern era of coronary thrombolysis: Benefit or detriment?

R. Becker, J. Foley, J. A. Foley, 1996, Cardiovascular Drugs and Therapy.

Biological and pharmacological aspects of perioperative hemorrhagic complications associated with oral platelet-directed antithrombotic agents. Focus on isolated coronary artery bypass grafting and oral irreversible P2Y(12) receptor antagonists.

R. Becker, 2009, Thrombosis research.

Reperfusion of Nonviable Myocardium: Lessons from Thrombolytic Therapy

R. Becker, 1990 .

Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial

A. Siegbahn, L. Wallentin, R. Becker, 2018, Journal of the American Heart Association.

Application of an Actively Reversible Direct Factor IXa Inhibitor as an Anticoagulation Strategy in Patients Undergoing Percutaneous Coronary Intervention

R. Becker, S. Zelenkofske, Mauricio G. Cohen, 2010 .

The evolution of platelet‐directed pharmacotherapy

R. Becker, S. Smyth, Richard C. Becker, 2009, Journal of thrombosis and haemostasis : JTH.

Thrombotic preparedness in aging: a translatable construct for thrombophilias?

R. Becker, 2007, Journal of Thrombosis and Thrombolysis.

Ticagrelor in patients with heart failure after acute coronary syndromes-Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.

C. Cannon, L. Wallentin, R. Becker, 2019, American heart journal.

Admission Levels of DKK1 (Dickkopf-1) Are Associated With Future Cardiovascular Death in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial

A. Siegbahn, L. Wallentin, R. Becker, 2019, Arteriosclerosis, thrombosis, and vascular biology.

Ischaemic Events and Stent Thrombosis following Planned Discontinuation of Study Treatment with Ticagrelor or Clopidogrel in the PLATO Study

C. Cannon, K. Mahaffey, D. Ardissino, 2018, Thrombosis and Haemostasis.

Rapid resolution of acute cor pulmonale with recombinant tissue plasminogen activator.

J. Gore, R. Becker, M. Thompson, 1989, Chest.

Reversal of Antithrombotic Therapy

R. Becker, 2017, JACC. Basic to translational science.

TICAGRELOR VERSUS CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROMES UNDERGOING CORONARY ARTERY BY-PASS SURGERY: RESULTS FROM THE PLATO TRIAL

C. Held, C. Cannon, K. Mahaffey, 2010 .

Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome

L. Wallentin, R. Becker, J. Alexander, 2010, Thrombosis and Haemostasis.

Thrombogenesis in atrial fibrillation: contributing mechanisms and natural history

R. Becker, 2008, Journal of Thrombosis and Thrombolysis.

Antiplatelet therapy in prevention of cardio- and venous thromboembolic events

S. Steinhubl, H. Dauerman, E. Hylek, 2014, Journal of Thrombosis and Thrombolysis.

The emergence of thrombocardiolgy

R. Becker, 2005, Journal of Thrombosis and Thrombolysis.

The Importance of Factor Xa Regulatory Pathways in Vascular Thromboresistance: Focus on Protein Z

R. Becker, 2005, Journal of Thrombosis and Thrombolysis.

COX-2 inhibitors

R. Becker, 2003, Texas Heart Institute journal.

The biology, utilization, and attenuation of C-reactive protein in cardiovascular disease: part I.

R. Becker, A. Armani, 2005, American heart journal.

Examining biology and pharmacology-based hypotheses in the PLATO trial

R. Becker, 2010, Journal of Thrombosis and Thrombolysis.

Incidence and Outcomes of Gastrointestinal Hemorrhage in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: Results From the ROCKET AF Trial

Manesh R. Patel, D. Singer, R. Califf, 2012 .

Thrombolytic agents and anticoagulants

R. Becker, 1993, Cardiovascular Drugs and Therapy.

Unravelling the mystery of the TACT trial

P. Ellis, R. Becker, 2009 .

Bivalirudin, thrombin and platelets: clinical implications and future directions.

S. Steinhubl, F. Jaffer, R. Becker, 2003, The Journal of invasive cardiology.

Apixaban: an emerging oral factor Xa inhibitor

R. Becker, Christopher Roser-Jones, 2009, Journal of Thrombosis and Thrombolysis.

Variant Angina Pectoris

J. Alpert, R. Becker, R. C. Becker, 1987 .

Nocturnal diaphoresis and coronary artery spasm. Contribution of the parasympathetic nervous system.

J. Alpert, R. Becker, M. Giuliani, 1987, Cleveland Clinic journal of medicine.

Beta-adrenergic blockade in the thrombolytic era.

R. Becker, 1992, Cardiology.

Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.

L. Wallentin, R. Becker, J. Cornel, 2012, American heart journal.

Thrombolytic Therapy: An Orchestra without a Conductor

R. Becker, 1993 .

Recurrent myocardial ischemia following thrombolytic therapy: guidelines for practicing clinicians.

R. Becker, 1992, American heart journal.

The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa Inhibitors (SYNERGY) trial.

R. Becker, 2005, American heart journal.

Primary tumors of the heart: a review with emphasis on diagnosis and potential treatment modalities.

R. Becker, J. Loeffler, D. Underwood, 1985, Seminars in surgical oncology.

Editor’s page: fundamentals in neurocardiology

R. Becker, 2008, Journal of Thrombosis and Thrombolysis.

Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor

J. Lucas, D. Cyr, R. Becker, 2012, Thrombosis and Haemostasis.

Hirudin: Its biology and clinical use

C. Cannon, R. Becker, 1994, Journal of Thrombosis and Thrombolysis.

Abstract 148: Efficacy and Safety of Rivaroxaban Compared with Warfarin Among Elderly Patients with Nonvalvular Atrial Fibrillation in the ROCKET-AF Trial

G. Breithardt, D. Singer, R. Califf, 2012, Stroke.

Short-Term Comparative Outcomes Associated with the Use of GP IIb/IIIa Antagonists in Patients Undergoing Coronary Intervention

W. Rand, R. Becker, C. Kimmelstiel, 2001, Journal of Thrombosis and Thrombolysis.

Factor Xa-A Pleuripotential Protease

R. Becker, 2003, Journal of Thrombosis and Thrombolysis.

A comparison of heparin strategies after thrombolytic therapy.

J. Gore, R. Becker, S. Ball, 1993, American heart journal.

A compmison~ of 'heparin @rategiSes after thrombotytic therapy

J. Gore, R. Becker, S. Ball, 1993 .

Tissue plasminogen activator and intracranial hemorrhage.

J. Gore, R. Becker, 1990, Annals of internal medicine.

Reversal of novel oral anticoagulants.

R. Becker, E. Abo-salem, E. Abo‐salem, 2016, Current opinion in pharmacology.

Plasmin-Mediated Proteolysis of Vascular Endothelial Cell Heparin Releasable Tissue Factor Pathway Inhibitor

R. Becker, F. Spencer, Youfu Li, 2003, Journal of Thrombosis and Thrombolysis.

Novel inhibitors of factor X for use in cardiovascular diseases

R. Becker, F. Spencer, 2000, Current cardiology reports.

The impact of medical therapy on hemorrhagic complications following coronary artery bypass grafting.

J. Alpert, R. Becker, 1990, Archives of internal medicine.

Monoclonal Antibody-Based Immunotherapy and Its Role in the Development of Cardiac Toxicity

R. Becker, S. Sadayappan, C. Thangavel, 2020, Cancers.

Hirudin-Based Anticoagulant Strategies for Patients with Suspected Heparin-Induced Thrombocytopenia Undergoing Percutaneous Coronary Interventions and Bypass Grafting

R. Becker, 2000, Journal of Thrombosis and Thrombolysis.

Recombinant t-PA and platelet activity.

R. Becker, 1990, Cleveland Clinic journal of medicine.

Optimizing Heparin Compounds: A Working Construct for Future Antithrombotic Drug Development

R. Becker, 2004, Journal of Thrombosis and Thrombolysis.

New anticoagulants--the path from discovery to clinical practice.

R. Becker, J. Lohrmann, 2008, The New England journal of medicine.

The heparin rebound phenomenon—Does it offer insights toward understanding the pathobiology of coronary thrombosis and its treatment?

R. Becker, 2005, Journal of Thrombosis and Thrombolysis.

DVT: A New Era in Anticoagulant Therapy DVT: A New Era in Anticoagulant Therapy

R. Becker, N. Mackman, 2010 .

The importance of VTE prevention after orthopaedic surgery

R. Becker, 2009, The Lancet.

Vasopressin Therapy of Hemorrhagic Complications Following Coronary Artery Bypass Grafting-Reply

J. Alpert, R. Becker, 1991 .

Consensus Document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting

Deepak L. Bhatt, D. Faxon, J. Eikelboom, 2011, Thrombosis and Haemostasis.

Responses of mental stress-induced myocardial ischemia to escitalopram treatment: background, design, and method for the Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment trial.

C. O'connor, R. Krishnan, R. Becker, 2012, American Heart Journal.

C. O'connor, R. Krishnan, R. Becker, 2012, American heart journal.

Serum gamma-glutamyl transpeptidase and chronic alcoholism

R. Becker, E. Mezey, R. Bozian, 1985, Digestive Diseases and Sciences.

Abstract 152: Predictors of Intracranial Hemorrhage Among Anticoagulated Patients with Atrial Fibrillation: Insights from the Rivaroxaban Once-daily oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)

G. Breithardt, D. Singer, R. Califf, 2012, Stroke.

Circadian variations in cardiovascular disease.

R. Becker, J. Corrao, 1989, Cleveland Clinic journal of medicine.

Thrombogenesis in atrial fibrillation contributing mechanisms and natural history

R. Becker, 2008, Journal of Thrombosis and Thrombolysis.

The biochemistry, enzymology and pharmacology of non-vitamin K anticoagulant drug reversal agents and antidotes

R. Becker, 2016, Journal of Thrombosis and Thrombolysis.

Adjuvant antiplatelet strategies in coronary thrombolysis.

J. Gore, R. Becker, 1991, Circulation.

Clinical utility of electrocardiographic ST-segment area for predicting unsatisfactory outcomes following thrombolytic therapy

R. Becker, J. Hébert, T. Hurley, 2005, Journal of Thrombosis and Thrombolysis.

Antithrombotic Therapy in Acute Coronary Syndrome: How Far Up the Coagulation Cascade Will We Go?

B. Sullenger, R. Becker, B. Woodruff, 2010, Current cardiology reports.

Rapidly regulating platelet activity in vivo with an antidote controlled platelet inhibitor.

B. Sullenger, R. Becker, S. Nimjee, 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

Introductory article : clinical highlights and future directions

R. Becker, 1990 .

Cardiovascular disease in women: scope of the problem.

R. Becker, J. Corrao, 1990, Cardiology.

Coronary heart disease risk factors in women.

R. Becker, I. Ockene, G. Hamilton, 1990, Cardiology.

The Impact of Heparin Compounds on Cellular Inflammatory Responses: A Construct for Future Investigation and Pharmaceutical Development

R. Becker, E. Elsayed, Essam F. Elsayed, 2003, Journal of Thrombosis and Thrombolysis.

NLRC4 Inflammasome Is an Important Regulator of Interleukin-18 Levels in Patients With Acute Coronary Syndromes: Genome-Wide Association Study in the PLATelet inhibition and patient Outcomes Trial (PLATO)

E. Hagström, N. Eriksson, A. Syvänen, 2015, Circulation. Cardiovascular genetics.

Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: Insights from the Platelet Inhibition and Patient Outcomes trial.

A. Siegbahn, L. Wallentin, R. Becker, 2015, American heart journal.

Thrombotic thrombocytopenic purpura in a patient with systemic lupus erythematosus.

R. Becker, M. Giuliani, J. Weick, 1985, Cleveland Clinic quarterly.

A novel homozygous premature stop mutation in TNNT2 associates with Feline cardiomyopathy

R. Becker, S. Sadayappan, James W. McNamara, 2020 .

Surgical Revascularization in Women

R. Becker, 1990 .

Biomarker-Based Prediction of Recurrent Ischemic Events in Patients With Acute Coronary Syndromes.

C. Held, K. Mahaffey, A. Siegbahn, 2022, Journal of the American College of Cardiology.

Medication Errors in Acute Cardiac Care: An American Heart Association Scientific Statement From the Council on Clinical Cardiology Subcommittee on Acute Cardiac Care, Council on Cardiopulmonary and Critical Care, Council on Cardiovascular Nursing, and Council on Stroke

R. Kerber, L. Newby, C. Cannon, 2002, Circulation.

Studies of the interaction of ticagrelor with the P2Y13 receptor and with P2Y13-dependent pro-platelet formation by human megakaryocytes

A. Balduini, R. Becker, R. Storey, 2016, Thrombosis and Haemostasis.

Factor Xa—Protease Activated Receptor Interface: A Paradigm for Combination Pharmacotherapy

R. Becker, 2004, Journal of Thrombosis and Thrombolysis.

988-3 Is there a Circadian Variation in Anticoagulation Response to Hirudin Following Acute Myocardial Infarction?

C. Cannon, T. Henry, J. Loscalzo, 1995 .

988-1 Toward Establishing Anticoagulation Guidelines for Intravenous Heparin Administration Among Patients with Myocardial Infarction Given Tissue Plasminogen Activator

C. Cannon, J. Loscalzo, R. Becker, 1995 .

Radiation Exposure and Coronary Atherothrombosis

R. Becker, 2005, Journal of Thrombosis and Thrombolysis.

Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study.

E. Hagström, A. Siegbahn, L. Wallentin, 2016, European heart journal.

Are There Any Causal Relations Between Growth Differentiation Factor 15 and Outcomes in Patients With Acute Coronary Syndrome? : - A Report From the Plato Gwas Study

E. Hagström, N. Eriksson, A. Syvänen, 2013 .

USE AND OUTCOMES OF ANTIARRHYTHMIC THERAPY IN PATIENTS WITH ATRIAL FIBRILLATION RECEIVING ORAL ANTICOAGULATION: RESULTS FROM THE ROCKET AF TRIAL

R. Passman, D. Singer, R. Califf, 2014 .

Clinical Outcomes With Rivaroxaban in Patients Transitioned From Vitamin K Antagonist Therapy

G. Breithardt, D. Singer, R. Califf, 2013, Annals of Internal Medicine.

Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial

G. Breithardt, D. Singer, R. Califf, 2014, European heart journal.

The case for preoperative aspirin administration in patients undergoing elective CABG: is it open or closed?

R. Becker, Regina Kayse, 2016, Annals of translational medicine.

THE USE OF DUAL ANTIPLATELET THERAPY AND PATIENT OUTCOMES IN THOSE UNDERGOING PCI IN THE ROCKET AF TRIAL

D. Singer, R. Califf, G. Hankey, 2014 .

OBESITY PARADOX FOR STROKE IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH RIVAROXABAN AND WARFARIN IN THE ROCKET AF TRIAL

D. Singer, R. Califf, G. Hankey, 2014 .

Abstract 14365: Rivaroxaban is Associated with a Reduced Risk of Thromboembolic events and Hemorrhagic Stroke in Patient with Heart Failure: Insights from ROCKET AF

G. Breithardt, D. Singer, R. Califf, 2012 .

Abstract 15544: Rivaroxaban Compared with Warfarin in Patients with Atrial Fibrillation and Diabetes: A Subgroup Analysis of the ROCKET AF Trial

G. Breithardt, D. Singer, R. Califf, 2012 .

Seminars in thrombosis, thrombolysis and vascular biology. 4. Fibrinolysis.

R. Becker, 1991, Cardiology.

Genetic ablation of diabetes-associated gene Ccdc92 reduces obesity and insulin resistance in mice

R. Becker, Chenran Wang, G. Fan, 2022, iScience.

Beyond Thrombosis

R. Becker, J. Katz, K. Kolappa, 2011, Chest.

Primary prevention of coronary heart disease in women.

E. Meilahn, R. Becker, J. Corrao, 1995, Cardiology.

Applying management guidelines in clinical practice

R. Becker, 2007 .

Factor IXa as a target for pharmacologic inhibition in acute coronary syndrome.

R. Becker, M. Chan, C. Rusconi, 2011, Cardiovascular therapeutics.

First Clinical Application of an Actively Reversible Direct Factor IXa Inhibitor as an Anticoagulation Strategy in Patients Undergoing Percutaneous Coronary Intervention

R. Becker, S. Zelenkofske, Mauricio G. Cohen, 2010, Circulation.

Interventional Cardiology First Clinical Application of an Actively Reversible Direct Factor IXa Inhibitor as an Anticoagulation Strategy in Patients Undergoing Percutaneous Coronary Intervention

R. Becker, S. Zelenkofske, Mauricio G. Cohen, 2010 .

Coagulation and fibrinolytic protein kinetics in cardiopulmonary bypass

R. Becker, M. Yavari, 2007, Journal of Thrombosis and Thrombolysis.

DVT: a new era in anticoagulant therapy.

R. Becker, N. Mackman, 2010, Arteriosclerosis, thrombosis, and vascular biology.

Anticoagulant therapy during cardiopulmonary bypass

R. Becker, M. Yavari, 2008, Journal of Thrombosis and Thrombolysis.

21 – Hemostatic Aspects of Cardiovascular Medicine

R. Becker, S. Vemulapalli, 2013 .

Chapter 20 – Hemostatic Aspects of Cardiovascular Medicine

R. Becker, 2007 .

Factor IXa inhibitors as novel anticoagulants.

R. Becker, C. Rusconi, K. Becker, 2007, Arteriosclerosis, thrombosis, and vascular biology.

Factor IXa Inhibitors as Novel Anticoagulants R 1 Howard Factor IXa Inhibitors

R. Becker, C. Rusconi, K. Becker, 2007 .

Developing Antithrombotic and Thrombolytic Agents: The Role of Experimental Models

R. Becker, 1997 .

Recombinant tissue-type plasminogen activator: current concepts and guidelines for clinical use in acute myocardial infarction. Part II.

R. Becker, R. Harrington, 1991, American heart journal.

A clinical cardiology perspective of thrombophilias

R. Becker, 2010, Journal of Thrombosis and Thrombolysis.

Novel oral anticoagulants: pharmacology, coagulation measures, and considerations for reversal

R. Becker, L. Jackson, 2014, Journal of Thrombosis and Thrombolysis.

Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

G. Guyatt, C. Cannon, R. Becker, 2008, Chest.

Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

G. Guyatt, C. O'connor, R. Becker, 2004, Chest.

Massive hemolysis in clostridium perfringens infections

R. Becker, R. Savage, J. Weick, 1987, Journal of surgical oncology.

Toward understanding the 2019 Coronavirus and its impact on the heart

R. Becker, 2020, Journal of Thrombosis and Thrombolysis.

Stroke Prevention in Atrial Fibrillation

J. Piccini, R. Becker, Thomas W. Wallace, 2011, Cardiovascular Drugs and Therapy.

Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial

G. Breithardt, D. Singer, R. Califf, 2014, European heart journal.

Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial FibrillationClinical Perspective

G. Breithardt, D. Singer, R. Califf, 2013 .

Platelet functions beyond hemostasis

H. Dauerman, R. Becker, A. Weyrich, 2009, Journal of thrombosis and haemostasis : JTH.

Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta‐analysis

Deepak L. Bhatt, M. Reilly, J. Eikelboom, 2010, Journal of thrombosis and haemostasis : JTH.

Impact of Global Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical Trial

G. Breithardt, D. Singer, R. Califf, 2013, Journal of the American Heart Association.

Platelet biology and response to antiplatelet therapy in women: implications for the development and use of antiplatelet pharmacotherapies for cardiovascular disease.

M. Sabatine, H. Dauerman, R. Becker, 2012, Journal of the American College of Cardiology.

Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.

Deepak L. Bhatt, M. Price, R. Becker, 2010, Journal of the American College of Cardiology.

Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery.

C. Held, C. Cannon, K. Mahaffey, 2012, Journal of the American College of Cardiology.

Pediatric and Adult Ambulatory Blood Pressure Thresholds and Blood Pressure Load as Predictors of Left Ventricular Hypertrophy in Adolescents

Lisa J. Martin, B. Rosner, S. Daniels, 2021, Hypertension.

Cardiac rhabdomyosarcoma: case report with review of clinical and pathologic features.

N. Ratliff, R. Becker, R. Hobbs, 1984, Cleveland Clinic quarterly.

Inhibitors of platelet adhesion.

R. Becker, T. Kiefer, Todd L. Kiefer, 2009, Circulation.

Genetics and Genomics in the Management of Hemostasis and Thrombosis

R. Becker, F. Andreotti, 2010 .

CHAPTER 63 – Hemostasis and Thrombosis

R. Becker, F. Andreotti, 2009 .

Intramural hematoma of the thoracic aorta in a woman with neurofibromatosis.

R. Becker, N. Okike, O. Ali, 2002, The Annals of thoracic surgery.

Aptamers as Therapeutics.

B. Sullenger, R. Becker, S. Nimjee, 2017, Annual review of pharmacology and toxicology.

Genetic Regulation of Platelet Receptor Expression and Function Application in Clinical Practice and Drug Development

M. Sabatine, L. Becker, H. Dauerman, 2010 .

G-Protein–Coupled Receptors as Signaling Targets for Antiplatelet Therapy

S. Steinhubl, R. Becker, S. Goodman, 2009, Arteriosclerosis, thrombosis, and vascular biology.

Novel constructs for thrombin inhibition.

R. Becker, 2005, American heart journal.

Management of platelet-directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures.

M. Sabatine, H. Dauerman, R. Becker, 2009, Journal of the American College of Cardiology.

Management of Platelet-Directed Pharmacotherapy in Patients With Atherosclerotic Coronary Artery Disease Undergoing Elective Endoscopic Gastrointestinal Procedures

M. Sabatine, H. Dauerman, R. Becker, 2009, The American Journal of Gastroenterology.

Pathobiologic features and prevention of thrombotic complications associated with prosthetic heart valves: fundamental principles and the contribution of platelets and thrombin.

R. Becker, A. Turpie, P. Eisenberg, 2001, American heart journal.

The Genetics of Thrombosis

R. Becker, Svati H. Shah, S. Shah, 2010 .

Beyond coronary thrombolysis.

J. Alpert, R. Becker, 1988, Archives of internal medicine.

Mucinous cystic neoplasm (mucinous cystadenocarcinoma of low-grade malignant potential) of the pancreas: a clinicopathologic study of 130 cases.

R. Becker, L. Thompson, R. Przygodzki, 1999, The American journal of surgical pathology.

Hypercoagulable States in Cardiovascular Disease

R. Becker, M. Chan, F. Andreotti, 2008, Circulation.

Fibrinolytic and Antithrombotic Therapy: Theory, Practice, and Management

R. Becker, F. Spencer, 2000 .

Forum—Letter to the editorReply

R. Becker, 1991 .

Catheter thrombosis and percutaneous coronary intervention: fundamental perspectives on blood, artificial surfaces and antithrombotic drugs

R. Becker, R. Harrington, M. Chan, 2009, Journal of Thrombosis and Thrombolysis.

First-in-Human Experience of an Antidote-Controlled Anticoagulant Using RNA Aptamer Technology: A Phase 1a Pharmacodynamic Evaluation of a Drug-Antidote Pair for the Controlled Regulation of Factor IXa Activity

S. Steinhubl, R. Cannon, R. Becker, 2006, Circulation.

The biology, utilization, and attenuation of C-reactive protein in cardiovascular disease: part II.

R. Becker, A. Armani, 2005, American heart journal.

Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial.

G. Breithardt, D. Singer, R. Califf, 2013, Journal of the American College of Cardiology.

Impact of atrial fibrillation on the in-hospital and long-term survival of patients with acute myocardial infarction: a community-wide perspective.

J. Alpert, J. Gore, R. Goldberg, 1990, American heart journal.

A composite view of cardiac rupture in the United States National Registry of Myocardial Infarction.

R. M. Rubison, W. Weaver, J. Gore, 1996, Journal of the American College of Cardiology.

On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF

G. Breithardt, D. Singer, J. Piccini, 2015, Circulation.

Translation and Clinical Development of Antithrombotic Aptamers.

B. Sullenger, R. Becker, T. Povsic, 2016, Nucleic acid therapeutics.

Abstract 19281: Outcomes Following Cardioversion and Atrial Fibrillation Ablation in Patients Treated with Rivaroxaban and Warfarin in the ROCKET AF Trial

G. Breithardt, D. Singer, R. Califf, 2012 .

The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

G. Guyatt, C. O'connor, D. Mark, 2008, Chest.

Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation.

R. Becker, A. Waldo, V. Tapson, 2005, Journal of the American College of Cardiology.

Structure–function relationships of factor Xa inhibitors: implications for the practicing clinician

R. Becker, B. Steinberg, 2014, Journal of Thrombosis and Thrombolysis.

Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban

G. Breithardt, D. Singer, R. Califf, 2016, Heart.

North American Thrombosis Forum, AF Action Initiative Consensus Document.

Farzaneh A. Sorond, P. Libby, J. Mega, 2016, The American journal of medicine.

Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial.

R. Passman, G. Breithardt, D. Singer, 2014, Heart rhythm.

Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20–21, 2011, Salvador, Bahia, Brazil

L. Newby, C. Granger, E. Peterson, 2012, Journal of Thrombosis and Thrombolysis.

Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14–16, 2010, São Paulo, Brazil

R. Califf, P. Armstrong, H. White, 2010, Journal of Thrombosis and Thrombolysis.

Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AF

D. Singer, G. Hankey, J. Piccini, 2019, Cardiology and Therapy.

Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial.

D. Singer, G. Hankey, J. Piccini, 2015, Journal of the American College of Cardiology.

Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: Results from the ROCKET AF Trial.

G. Breithardt, D. Singer, G. Hankey, 2016, American heart journal.

Efficacy and Safety of Rivaroxaban in Patients With Heart Failure and Nonvalvular Atrial Fibrillation: Insights From ROCKET AF

G. Breithardt, D. Singer, R. Califf, 2013, Circulation. Heart failure.

Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Coronary Stenting: A North American Perspective: Executive Summary

Deepak L. Bhatt, D. Faxon, J. Eikelboom, 2011, Circulation. Cardiovascular interventions.

Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial).

G. Breithardt, D. Singer, G. Hankey, 2017, The American journal of cardiology.

Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation

G. Breithardt, D. Singer, G. Hankey, 2016, Circulation.

Warfarin in vulnerable older adults with atrial fibrillation

R. Becker, S. Gharacholou, 2009, Journal of Thrombosis and Thrombolysis.

Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial

G. Breithardt, D. Singer, M. Fava, 2018, Journal of the American Heart Association.

Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF

D. Singer, G. Hankey, J. Piccini, 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

Cell-Based Models of Coagulation: A Paradigm in Evolution

R. Becker, 2005, Journal of Thrombosis and Thrombolysis.

Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF

G. Breithardt, D. Singer, R. Califf, 2012, The Lancet Neurology.

Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial.

G. Breithardt, D. Singer, R. Califf, 2014, European heart journal.

Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF

G. Breithardt, D. Singer, G. Hankey, 2018, American heart journal.

End of Study Transition From Study Drug to Open-Label Vitamin K Antagonist Therapy: The ROCKET AF Experience

G. Breithardt, D. Singer, R. Califf, 2013, Circulation. Cardiovascular quality and outcomes.

Thromboembolism and antithrombotic therapy in patients with heart failure in sinus rhythm: current status and future directions.

C. O'connor, G. Felker, M. Metra, 2011, Circulation. Heart failure.

Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), october 18–19, 2012, Belo Horizonte, Minas Gerais, Brazil

R. Giugliano, C. Granger, K. Mahaffey, 2013, Journal of Thrombosis and Thrombolysis.

Nursing, and Council on Stroke Care, Council on Cardiopulmonary and Critical Care, Council on Cardiovascular Statement From the Council on Clinical Cardiology Subcommittee on Acute Cardiac Medication Errors in Acute Cardiac Care : An American Heart Association Scientific

R. Kerber, P. O'Gara, R. Becker, 2013 .

Antithrombotic therapy practices in US hospitals in an era of practice guidelines.

A. Shillington, D. Ballard, R. Becker, 2005, Archives of internal medicine.

When guidelines collide...

R. Becker, F. Spencer, 2004, American heart journal.

A randomized, multicenter trial of weight-adjusted intravenous heparin dose titration and point-of-care coagulation monitoring in hospitalized patients with active thromboembolic disease. Antithrombotic Therapy Consortium Investigators.

R. Hendel, R. Becker, F. Spencer, 1999, American heart journal.

Practice Guidelines (8th Edition) of Chest Physicians Evidence-Based Clinical Antithrombotic Therapy: American College The Perioperative Management of

J. Douketis, R. Becker, P. Berger, 2008 .

Perioperatives Management der antithrombotischen Therapie: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8. Auflage)

J. Douketis, R. Becker, P. Berger, 2008 .

Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.

C. Held, L. Wallentin, R. Becker, 2015, American heart journal.

Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrel

C. Held, C. Cannon, K. Mahaffey, 2014, International journal of cardiology.

Ticagrelor Versus Clopidogrel in Elderly Patients With Acute Coronary Syndromes: A Substudy From the Prospective Randomized PLATelet Inhibition and Patient Outcomes (PLATO) Trial

C. Cannon, K. Mahaffey, R. Bach, 2012 .

Contemporary Reviews in Interventional Cardiology Platelet-Mediated Thrombosis and Drug-Eluting Stents

M. Price, S. Steinhubl, H. Dauerman, 2011 .

Clopidogrel use and bleeding after coronary artery bypass graft surgery.

D. Mark, C. Granger, L. Shaw, 2008, American heart journal.

Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.

R. Califf, Á. Avezum, E. Antman, 2004, JAMA.

Aspirin dosing frequency in the primary and secondary prevention of cardiovascular events

R. Becker, Joonseok Kim, 2016, Journal of Thrombosis and Thrombolysis.

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial

B. J. Barratt, L. Wallentin, R. Becker, 2010, The Lancet.

Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease.

R. Becker, M. Furman, C. Valeri, 1998, Journal of the American College of Cardiology.

A phase 1 ascending dose study of a subcutaneously administered factor IXa inhibitor and its active control agent

R. Becker, S. Zelenkofske, J. Alexander, 2012, Journal of thrombosis and haemostasis : JTH.

Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy.

R. Becker, R. Mehran, T. Povsic, 2011, European heart journal.

A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR Phase IIb trial.

J. Kasprzak, R. Becker, R. Mehran, 2011, American heart journal.

Platelet inhibition with cangrelor in patients undergoing PCI.

Gregg W Stone, Deepak L. Bhatt, Deepak L Bhatt, 2009, The New England journal of medicine.

Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillation

R. Becker, S. Pokorney, M. Sherwood, 2013, Journal of Thrombosis and Thrombolysis.

Massive Overdose of Cardizem CD

R. Becker, C. Aaron, L. Laifer, 1996 .

Epigenetic modification: a regulatory mechanism in essential hypertension

Lisa J. Martin, R. Becker, E. Urbina, 2019, Hypertension Research.

Atherothrombotic Disorders: New Insights From Hematology

R. Becker, F. Andreotti, 2005, Circulation.

Inherited Disorders of the Hemostatic System Predisposing to Arterial Thrombosis

R. Becker, F. Andreotti, 2005 .

Atherothrombotic Disorders New Insights from Hematology Thrombophilias and Their Evaluation Inherited Disorders of the Hemostatic System Predisposing to Arterial Thrombosis Special Report

R. Becker, F. Andreotti, 2005 .

Antithrombotic therapy: new areas to understand efficacy and bleeding

R. Becker, James W. Wisler, 2014, Expert opinion on therapeutic targets.

A randomized, repeat‐dose, pharmacodynamic and safety study of an antidote‐controlled factor IXa inhibitor

R. Becker, J. Alexander, R. Harrington, 2008, Journal of thrombosis and haemostasis : JTH.

Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: results from the PLATelet Inhibition and Patient Outcomes (PLATO) study.

A. Larsson, A. Budaj, A. Siegbahn, 2013, Clinical chemistry.

Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study.

A. Budaj, A. Siegbahn, L. Wallentin, 2012, American heart journal.

The worcester venous thromboembolism study

R. Goldberg, R. Becker, F. Spencer, 2006, Journal of General Internal Medicine.

The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism.

R. Goldberg, R. Becker, F. Spencer, 2006, Journal of general internal medicine.

Seminars in Thrombosis, Thrombolysis and Vascular Biology

R. Becker, 1991 .

Seminars in thrombosis, thrombolysis and vascular biology. 3. Platelet activity in cardiovascular disease.

R. Becker, 1991, Cardiology.

Current references: Thromboembolism in congestive cardiomyopathy

R. Becker, F. Spencer, 1995, Journal of Thrombosis and Thrombolysis.

Clinical and Research Applications of Markers of Thrombosis

R. Becker, M. Patel, 2006 .

Adaptive and maladaptive cardiovascular responses in human sepsis.

R. Becker, S. Voyce, 1991, American heart journal.

Linking Biochemistry, Vascular Biology, and Clinical Events in Acute Coronary Syndromes

R. Becker, A. Armani, 2003 .

Linking Biochemical, Pathologic, and Clinical Events in Acute Coronary Syndromes

R. Becker, 1999 .

CHAPTER 35 – Atherothrombosis and Coronary Artery Disease

R. Becker, P. Goldschmidt-Clermont, N. Lopes, 2007 .

Genetic Modifiers of Hereditary Neuromuscular Disorders and Cardiomyopathy

R. Becker, S. Sadayappan, Sholeh Bazrafshan, 2021, Cells.

Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome

K. Mahaffey, S. Hazen, R. Becker, 2011, Journal of Thrombosis and Thrombolysis.

Adjunctive Pharmacologic Treatment: Focus on the Development of Low Molecular Weight Heparins

R. Becker, F. Spencer, 2004, Journal of Thrombosis and Thrombolysis.

An update on translational and early trials in coronary interventions

R. Becker, A. Zachariah, 2014 .

Acquired factor X amyloidosis 1 deficiency in systemic

R. Becker, R. Tubbs, F. Lucas, 2013 .

Acquired factor X deficiency in systemic amyloidosis.

R. Becker, R. Tubbs, F. Lucas, 1987, Cleveland Clinic journal of medicine.

Prevalence and relevance of abnormal glucose metabolism in acute coronary syndromes: insights from the PLATelet inhibition and patient Outcomes (PLATO) trial

A. Budaj, D. Wojdyla, A. Siegbahn, 2019, Journal of Thrombosis and Thrombolysis.

Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention: A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis

C. Cannon, W. Weaver, D. Ardissino, 2010, Circulation.

Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapy

G. Ginsburg, J. Lucas, D. Voora, 2012, Journal of Thrombosis and Thrombolysis.

Clopidogrel‐Associated Bleeding and Related Complications in Patients Undergoing Coronary Artery Bypass Grafting

R. Becker, G. Schumock, C. Frye, 2008, Pharmacotherapy.

Platelets from genome to proteome and beyond

R. Becker, 2007, Journal of Thrombosis and Thrombolysis.

Guidelines for the Management of Patients with Acute Myocardial Infarction

R. Becker, F. Spencer, 2004, Journal of Thrombosis and Thrombolysis.

Circadian variations in acute myocardial infarction: patients or health care delivery?

R. Becker, F. Spencer, 2003, Journal of the American College of Cardiology.

Current management of acute myocardial infarction.

J. Alpert, R. Becker, R. C. Becker, 1989, Current problems in cardiology.

A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.

C. Cannon, W. Rogers, T. Henry, 1994, Journal of the American College of Cardiology.

Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.

C. Cannon, K. Mahaffey, R. Bach, 2011, Circulation. Cardiovascular quality and outcomes.

Management Strategies for a Better Outcome in Unstable Coronary Artery Disease

R. Campbell, J. Cleland, C. Conti, 1998, Clinical cardiology.

Outcome and profile of women and men presenting with acute coronary syndromes: a report from TIMI IIIB. TIMI Investigators. Thrombolysis in Myocardial Infarction.

E. Braunwald, C. Cannon, P. Stone, 1997, Journal of the American College of Cardiology.

Comparison of Clinical Outcomes for Women and Men after Acute Myocardial Infarction

E. Braunwald, J. Gore, G. Knatterud, 1994, Annals of Internal Medicine.

Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials.

C. Cannon, L. Wallentin, R. Becker, 2013, Stroke.

Early assessment and in-hospital management of patients with acute myocardial infarction at increased risk for adverse outcomes: a nationwide perspective of current clinical practice. The National Registry of Myocardial Infarction (NRMI-2) Participants.

J. Gore, W. Rogers, J. Hilbe, 1998, American heart journal.

The n e w e n g l a n d j o u r n a l of m e d i c i n e Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease

A. Skene, C. Held, C. Cannon, 2017 .

Platelet-Mediated Thrombosis and Drug-Eluting Stents

M. Price, S. Steinhubl, H. Dauerman, 2011, Circulation. Cardiovascular interventions.

Evolution of the Coronary Care Unit

R. Becker, J. Katz, 2010, Cardiac Intensive Care.

CHAPTER 1 – Evolution of the Coronary Care Unit: Past, Present, and Future

R. Becker, J. Katz, 2010 .

Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer.

N Franklin Adkinson, Jeffrey Sailstad, Paul W Armstrong, 2016, The Journal of allergy and clinical immunology.

Are at Least 12 Months of Dual Antiplatelet Therapy Needed for All Patients With Drug-Eluting Stents? Response to Becker and Helmy

R. Becker, T. Helmy, 2015 .

Are at least 12 months of dual antiplatelet therapy needed for all patients with drug-eluting stents? Not all patients with drug-eluting stents need at least 12 months of dual antiplatelet therapy.

R. Becker, T. Helmy, 2015, Circulation.

Bedside coagulation monitoring in heparin-treated patients with active thromboembolic disease: a coronary care unit experience.

R. Becker, J. Cyr, S. Ball, 1994, American heart journal.

A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial.

J. Kasprzak, R. Becker, R. Mehran, 2013, European heart journal.

Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial

K. Mahaffey, L. Wallentin, R. Becker, 2015, European journal of preventive cardiology.

Sex differences in mortality following acute coronary syndromes.

R. Califf, E. Topol, L. Newby, 2009, JAMA.

Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library.

R. Califf, G. Stone, K. Mahaffey, 2004, American heart journal.

Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study.

D. Voora, N. Eriksson, L. Wallentin, 2018, Platelets.

Sex differences in platelet reactivity and cardiovascular and psychological response to mental stress in patients with stable ischemic heart disease: insights from the REMIT study.

C. O'connor, R. Becker, C. Kuhn, 2014, Journal of the American College of Cardiology.

Depressive Symptoms and Mental Stress–Induced Myocardial Ischemia in Patients With Coronary Heart Disease

C. O'connor, R. Becker, M. Kuchibhatla, 2013, Psychosomatic medicine.

Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial.

C. O'connor, R. Becker, M. Kuchibhatla, 2013, JAMA.

Advancing biomarker science in the 21st century.

R. Becker, 2009, Circulation. Cardiovascular interventions.

Phase 1b Randomized Study of Antidote-Controlled Modulation of Factor IXa Activity in Patients With Stable Coronary Artery Disease

S. Steinhubl, R. Becker, Mauricio G. Cohen, 2008, Circulation.

Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction.

E. Antman, R. Becker, C. Veyrat‐Follet, 2003, British journal of clinical pharmacology.

Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and nonâ•’STâ•’segment elevation myocardial infarction

E. Antman, R. Becker, C. Veyrat‐Follet, 2003 .

Registry of Myocardial Infarction Seasonal distribution of acute myocardial infarction in the second National

R. Goldberg, R. Becker, J. Gore, 2011 .

Seasonal distribution of acute myocardial infarction in the second National Registry of Myocardial Infarction.

J. Gore, R. Goldberg, R. Becker, 1998, Journal of the American College of Cardiology.

Seminars in thrombosis, thrombolysis and vascular biology. 1. The vascular endothelium.

R. Becker, 1991, Cardiology.

Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group V: Management of Cardiovascular-Renal Complications

R. Bonow, S. Hunt, P. O'Gara, 2002, Circulation.

How Should Patients Requiring Dual Antiplatelet Therapy be Managed When Undergoing Elective Endoscopic Gastrointestinal Procedures?

R. Becker, Tracy Y. Wang, M. Sherwood, 2011, Current treatment options in cardiovascular medicine.

Biomarkers for outcomes following acute coronary syndromes

R. Becker, Ravi Karra, R. Karra, 2010 .

Increased Post‐procedural Non‐gastrointestinal Adverse Events After Outpatient Colonoscopy in High‐risk Patients

U. Ladabaum, S. Gross, D. Lieberman, 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Circulating MicroRNA Profiling in Non-ST Elevated Coronary Artery Syndrome Highlights Genomic Associations with Serial Platelet Reactivity Measurements

H. White, S. Gregory, R. Becker, 2020, Scientific Reports.

The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

G. Guyatt, C. O'connor, D. Mark, 2008, Chest.

Effect of genetic variations on ticagrelor plasma levels and clinical outcomes.

D. Voora, E. Hagström, N. Eriksson, 2015, European heart journal.

Pharmacogenetics of Antiplatelet Therapy

R. Becker, Patrick L. Daly, 2014, Current Atherosclerosis Reports.

Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudy

A. Siegbahn, L. Wallentin, R. Becker, 2021, Platelets.

Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial.

C. Held, K. Mahaffey, A. Budaj, 2011, European heart journal.

Genome-wide association and Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome.

N. Eriksson, A. Syvänen, B. J. Barratt, 2016, Human molecular genetics.

The role of blood viscosity in the development and progression of coronary artery disease.

R. Becker, R C Becker, 1993, Cleveland Clinic journal of medicine.

Subclinical Systolic and Diastolic Dysfunction Is Evident in Youth With Elevated Blood Pressure

Lisa J. Martin, B. Rosner, S. Daniels, 2020, Hypertension.

Prediction of Ambulatory Hypertension Based on Clinic Blood Pressure Percentile in Adolescents: The SHIP AHOY Study

Lisa J. Martin, B. Rosner, S. Daniels, 2018, Hypertension.

Early-onset obesity and the unwanted promise of thrombosis

R. Becker, 2011, Journal of Thrombosis and Thrombolysis.

Modulating atherothrombosis

R. Becker, 2006, Journal of Thrombosis and Thrombolysis.

Atherothrombosis at a distance: contributing role of existing large-burden vascular disease, circulating biosignals and modulating extravascular tissues.

R. Becker, 2007, Thrombosis research.

Off-target properties of pharmacotherapy and the importance of mechanistic investigations in early clinical phase drug development

R. Becker, 2007, Journal of Thrombosis and Thrombolysis.

Aspirin dosing in cardiovascular disease prevention and management: an update

R. Becker, Leila Ganjehei, 2015, Journal of Thrombosis and Thrombolysis.

Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial

G. Breithardt, D. Singer, G. Hankey, 2016, Journal of the American Heart Association.

Evaluation of dose requirements for prolonged bivalirudin administration in patients with renal insufficiency and suspected heparin-induced thrombocytopenia

R. Becker, J. Washam, James W. Wisler, 2012, Journal of Thrombosis and Thrombolysis.

Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF

G. Breithardt, H. Crijns, P. Mclaughlin, 2016, Journal of the American Heart Association.

Biomarker Concentrations and Their Temporal Changes in Patients With Myocardial Infarction and Nonobstructive Compared With Obstructive Coronary Arteries: Results From the PLATO Trial.

A. Budaj, A. Siegbahn, L. Wallentin, 2022, Journal of the American Heart Association.

Cystatin C and Estimated Glomerular Filtration Rate as Predictors for Adverse Outcome in Patients with St-elevation and Non–st-elevation Acute Coronary Syndromes: Results from the Platelet Inhibition and Patient Outcomes (plato) Study

A. Budaj, A. Siegbahn, L. Wallentin, 2022 .

Coronary artery bypass surgery in women

J. Alpert, R. Becker, J. Alpert, 1988, Clinical cardiology.

Preoteomics, metabolomics and progenitor cells in acute coronary syndromes

R. Becker, F. Andreotti, 2006, Journal of Thrombosis and Thrombolysis.

Preoteomics, metabolomics and circulating endothelial progenitor cells in acute coronary syndromes

Richard C. Becker, R. Becker, 2006, Journal of Thrombosis and Thrombolysis.

Highlights from the II international symposium of thrombosis and anticoagulation (ISTA), October 22–23, 2009, São Paulo, Brazil

C. Granger, R. Becker, R. Lopes, 2010, Journal of Thrombosis and Thrombolysis.

Abstract 16293: A Whole Blood RNA Signature Accurately Classifies Multiple Measures of Platelet Function on Aspirin in Healthy Volunteers and Highlights a Common Underlying Pathway

G. Ginsburg, J. Lucas, D. Voora, 2010 .

Evaluating chest pain in patients with post COVID conditions permission to think outside of the box

R. Becker, 2023, Journal of Thrombosis and Thrombolysis.

Hemostasis and thrombosis in older adults

R. Becker, S. Gharacholou, S. M. Gharacholou, 2009, Journal of Thrombosis and Thrombolysis.

Delivery of Optimized Anticoagulant Therapy: Consensus Statement from the Anticoagulation Forum

E. Hylek, R. Becker, D. Witt, 2008, The Annals of pharmacotherapy.

Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial

G. Breithardt, D. Singer, R. Califf, 2014, Stroke.

South Asian-Specific MYBPC3Δ25bp Deletion Carriers Display Hypercontraction and Impaired Diastolic Function Under Exercise Stress

R. Becker, Jack Rubinstein, S. Sadayappan, 2021, Frontiers in Cardiovascular Medicine.

Critical pathways : a review. Committee on Acute Cardiac Care, Council on Clinical Cardiology, American Heart Association.

C. Cannon, R. Becker, J. Hochman, 2000, Circulation.

Differential modulation of polyunsaturated fatty acids in patients with myocardial infarction treated with ticagrelor or clopidogrel

R. Becker, R. Lopes, L. Newby, 2021, Cell reports. Medicine.

CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects.

E. Tai, Chi‐Hang Lee, A. Low, 2012, Pharmacogenomics.

Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers.

B. Sullenger, R. Becker, D. Ginsburg, 2007, Oligonucleotides.

Enoxaparin, a Low Molecular Weight Heparin, Inhibits Platelet-Dependent Prothrombinase Assembly and Activity by Factor-Xa Neutralization

R. Becker, Long-bin Liu, F. Spencer, 2000, Journal of Thrombosis and Thrombolysis.

Dronedarone and vitamin K antagonists: a review of drug-drug interactions.

R. Becker, M. Fiuzat, Shailesh C. Shirolkar, 2010, American heart journal.

Anticoagulants: Pharmacokinetics, Mechanisms of Action, and Indications.

R. Becker, J. Washam, T. Dewald, 2018, Neurosurgery clinics of North America.

Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF

G. Breithardt, D. Singer, G. Hankey, 2018, European heart journal. Quality of care & clinical outcomes.

A Novel Homozygous Intronic Variant in TNNT2 Associates With Feline Cardiomyopathy

R. Becker, S. Sadayappan, James W. McNamara, 2020, Frontiers in Physiology.

Polymorphism of the cystatin C gene in patients with acute coronary syndromes: Results from the PLATelet inhibition and patient Outcomes study.

N. Eriksson, A. Budaj, B. J. Barratt, 2014, American heart journal.

Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial.

G. Breithardt, D. Singer, G. Hankey, 2016, American heart journal.

Platelet Biology: The Role of Platelets in Hemostasis, Thrombosis and Inflammation

R. Becker, 2008 .

Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation).

G. Breithardt, D. Singer, R. Califf, 2014, Journal of the American College of Cardiology.

Funding opportunities for clinical investigators in the early stages of career development in cardiovascular research

R. Becker, R. Mentz, 2013, Journal of Thrombosis and Thrombolysis.

Platelet aggregation and mental stress induced myocardial ischemia: Results from the Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT) study.

C. O'connor, R. Becker, C. Kuhn, 2015, American heart journal.

Platelet Aggregation and Mental Stress Induced Myocardial Ischemia: Results from the REMIT Study

C. O'connor, R. Becker, C. Kuhn, 2014, American heart journal.

Cardiac risk in noncardiac geriatric surgery.

R. Becker, 1986, Annals of internal medicine.

Dose Selection for a Direct and Selective Factor IXa Inhibitor and its Complementary Reversal Agent: Translating Pharmacokinetic and Pharmacodynamic Properties of the REG1 System to Clinical Trial Design

R. Becker, T. Povsic, S. Zelenkofske, 2011, Journal of Thrombosis and Thrombolysis.

A Thought Experiment in Contemporary Drug Development: Informed Bench‐to‐Bedside Strategies

R. Becker, 2013, Journal of the American Heart Association.

N 00014-94-C-0149 TECHNICAL REPORT 96-07 INCREASED PLATELET REACTIVITY AND CIRCULATING MONOCYTE-PLATELET AGGREGATES IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE

R. Becker, C. Valeri, H. Hechtman, 1999 .

Emerging paradigms, platforms, and unifying themes in biomarker science.

R. Becker, 2007, Journal of the American College of Cardiology.

The rapid proliferation of solicited content online journals: a quest to disseminate knowledge?

R. Becker, S. Sadayappan, V. Cotarlan, 2019, Journal of Thrombosis and Thrombolysis.

Cardiovascular disease in women: facts and statistics.

R. Becker, 1995, Cardiology.

The pharmacology of novel oral anticoagulants

R. Becker, T. Dewald, 2013, Journal of Thrombosis and Thrombolysis.

Emergence of factor IXa as a target for pharmacologic inhibition: editors page

R. Becker, 2007, Journal of Thrombosis and Thrombolysis.

The Versatile Platelet in Critical Illness

R. Becker, J. Katz, K. Kolappa, 2015 .

The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial

A. Budaj, R. Bach, L. Wallentin, 2014, European heart journal.

Mechanical failure of a St. Jude Medical prosthesis.

R. Becker, J. Moran, D. Orsinelli, 1991, The American journal of cardiology.

Nucleic acid aptamers in therapeutic anticoagulation

B. Sullenger, R. Becker, C. Rusconi, 2005, Thrombosis and Haemostasis.

Anticoagulation monitoring: Accurate results with patient self-testing in a multicenter trial

R. Becker, M. Andrew, J. Ansell, 1996 .

Cardiopulmonary Phenotypes of Post Acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2: A Narrative Review

R. Becker, Muhammad H Khan, 2021, Cardiology in review.

Outcomes of patients with atrial fibrillation and significant valvular lesions: Comparison of the effects of rivaroxaban and warfarin in the ROCKET AF trial

D. Singer, R. Califf, G. Hankey, 2013 .

A clinician's view of thrombotic disorders of the cardiovascular system.

R. Becker, 1998, Archives of pathology & laboratory medicine.

Translating Nucleic Acid Aptamers to Antithrombotic Drugs in Cardiovascular Medicine

B. Sullenger, R. Becker, T. Povsic, 2010, Journal of cardiovascular translational research.

Direct factor IXa inhibition with the RNA-aptamer pegnivacogin reduces platelet reactivity in vitro and residual platelet aggregation in patients with acute coronary syndromes

R. Becker, S. Zelenkofske, C. Bode, 2019, European heart journal. Acute cardiovascular care.

Cardiovascular medicine : practice and management

J. Alpert, R. Becker, 2001 .

Cardiovascular Disease in Women

J. Alpert, R. Becker, 1990 .

Comparison of clinical outcomes for women and men after acute myocardial infarction. The Thrombolysis in Myocardial Infarction Investigators.

E. Braunwald, J. Gore, G. Knatterud, 1994, Annals of internal medicine.

Inflammation and coronary artery disease: from pathophysiology to Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).

R. Becker, Atif Hassan, Mahboob Ali, 2018, Coronary artery disease.

Nocturnal diaphoresis in Prinzmetal angina.

J. Alpert, R. Becker, 1987, Annals of internal medicine.

Relationship between serum total cholesterol, infarct size, and early clinical outcome following acute myocardial infarction.

R. Becker, R. Lew, J. Corrao, 1992, Cardiology.

Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa (alphaIIb/beta3) receptor-directed platelet inhibition.

R. Becker, F. Spencer, Y. Li, 2001, American heart journal.

Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF.

G. Breithardt, D. Singer, G. Hankey, 2018, International journal of cardiology.

Noninvasive diagnosis of coronary heart disease in women.

R. Becker, P. Taylor, 1990, Cardiology.

Seasonal occurrence of acute myocardial infarction in the National Registry of myocardial infarction-2 (NRMI-2)

J. Gore, R. Goldberg, R. Becker, 1998 .

Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AF

G. Breithardt, D. Singer, G. Hankey, 2021, Heart rhythm O2.

Anticardiolipin antibodies in patients with unstable angina.

R. Becker, M. N. Díaz, 1994, Cardiology.

Platelet biology for the clinician-scientist: an evolution of understanding

R. Becker, 2008, Journal of Thrombosis and Thrombolysis.

Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel.

C. Cannon, A. Siegbahn, L. Wallentin, 2019, European heart journal. Acute cardiovascular care.

Outcomes After Cardioversion and Atrial Fibrillation Ablation in Patients Treated With Rivaroxaban and Warfarin in the ROCKET AF Trial

G. Breithardt, D. Singer, R. Califf, 2013 .

C. Cannon, W. Weaver, D. Ardissino, 2010, Circulation.

A legacy of words

R. Becker, 2018, Journal of Thrombosis and Thrombolysis.

C. Cannon, L. Wallentin, R. Becker, 2016, American Heart Journal.

Excess body weight does not adversely influence either bioavailability or anticoagulant activity of enoxaparin administered subcutaneously in acute coronary syndromes

E. Antman, R. Becker, F. Spencer, 2000 .

TICAGRELOR PLASMA LEVELS BUT NOT CLINICAL OUTCOMES ARE ASSOCIATED WITH TRANSPORTER AND METABOLISM ENZYME GENETIC POLYMORPHISMS

D. Voora, E. Hagström, N. Eriksson, 2014 .

G. Breithardt, D. Singer, G. Hankey, 2015, American heart journal.

Fibrinolytic and Antithrombotic Therapy: Theory, Practice, and Management

R. Becker, F. Spencer, Richard C. Becker, 2000 .

Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

A. Skene, C. Held, C. Cannon, 2009, The New England journal of medicine.

ROLE OF ADMISSION CARDIAC BIOMARKERS IN RISK STRATIFICATION OF PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION: INSIGHTS FROM THE PLATELET INHIBITION AND PATIENT OUTCOMES TRIAL

A. Siegbahn, L. Wallentin, R. Becker, 2014 .

Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

A. Skene, C. Held, C. Cannon, 2009, The New England journal of medicine.

Sex Differences in Platelet Reactivity and Cardiovascular and Psychological Response to Mental Stress in Patients With Stable Ischemic Heart Disease

C. O'connor, R. Becker, C. Kuhn, 2014 .

Medical publishing during the COVID-19 pandemic: then and now

R. Becker, C. Bode, 2021, Journal of Thrombosis and Thrombolysis.

An American Heart Association Scientific Statement From the Council on Clinical Cardiology Subcommittee on Acute Cardiac Care, Council on Cardiopulmonary and Critical Care, Council on Cardiovascular Nursing, and Council on Stroke

R. Kerber, C. Cannon, J. Freedman, 2002 .

Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

A. Skene, C. Held, C. Cannon, 2009, The New England journal of medicine.

Anticoagulation in Patients With COVID-19 Pneumonia-What Is the Optimal Intensity?

R. Becker, T. Ortel, 2023, JAMA internal medicine.

C. Held, C. Cannon, K. Mahaffey, 2014, Circulation.

Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery.

C. Held, C. Cannon, K. Mahaffey, 2012, Journal of the American College of Cardiology.

Cardiovascular Devices and Platelet Interactions: Understanding the Role of Injury, Flow, and Cellular Responses

S. Steinhubl, A. Finn, H. Dauerman, 2012, Circulation. Cardiovascular interventions.

Platelet-Mediated Thrombosis and Drug-Eluting Stents

M. Price, S. Steinhubl, H. Dauerman, 2011, Circulation. Cardiovascular interventions.

Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy).

C. Cannon, L. Wallentin, R. Becker, 2011, The American journal of cardiology.

Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.

C. Held, C. Cannon, K. Mahaffey, 2011, Journal of the American College of Cardiology.

Platelet P2Y12 receptor antagonist pharmacokinetics and pharmaco -dynamics: A foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies

R. Becker, P. Gurbel, 2010, Thrombosis and Haemostasis.

Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study.

A. Budaj, A. Siegbahn, L. Wallentin, 2012, Clinical chemistry.

A. Skene, C. Cannon, L. Wallentin, 2009, American heart journal.

Sex differences in mortality following acute coronary syndromes.

R. Califf, E. Topol, L. Newby, 2009, JAMA.

Inflammatory Response and Thrombosis in Older Individuals

R. Becker, J. Schlaudecker, 2014, Seminars in Thrombosis & Hemostasis.

Biomarker science: direction for the scientific community

R. Becker, 2009, Journal of Thrombosis and Thrombolysis.

Genome-wide association and Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome.

N. Eriksson, A. Syvänen, B. J. Barratt, 2016, Human molecular genetics.

Key References: Anticoagulation Monitoring

R. Becker, 2004, Journal of Thrombosis and Thrombolysis.

Heart Rhythm Disorders Outcomes After Cardioversion and Atrial Fibrillation Ablation in Patients Treated With Rivaroxaban and Warfarin in the ROCKET AF Trial

G. Breithardt, D. Singer, R. Califf, 2013 .

Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial.

D. Singer, G. Hankey, J. Piccini, 2015, Journal of the American College of Cardiology.

G. Breithardt, D. Singer, R. Califf, 2014, Journal of the American College of Cardiology.

Abstract 15879: Management of Major Bleeding Events in Patients Treated With Rivaroxaban Versus Warfarin: Results From the ROCKET AF Trial

G. Breithardt, D. Singer, R. Califf, 2013 .

Efficacy and Safety of Rivaroxaban in Patients with Diabetes and Nonvalvular Atrial Fibrillation : The ROCKET AF Trial

Keith, G. Breithardt, D. Singer, 2015 .

Marine omega-3 fatty acids and atherosclerosis.

R. Becker, J. Corrao, 1988, Annals of internal medicine.

The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: rationale and a summary of the available evidence from phase 3 clinical trials.

R. Becker, R. Lopes, A. Krishnamoorthy, 2015, American heart journal.

Massive hemolysis in clostridium perfringens infections

R. Becker, R. Savage, A. Pereira, 1987, Journal of surgical oncology.

Coronary thrombolysis in women.

R. Becker, 1990, The Cardiology.

Abstract 16914: On-treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF

G. Breithardt, D. Singer, J. Piccini, 2015, Circulation.